NanoLuc luciferase as a suitable fusion partner of recombinant antibody fragments for developing sensitive luminescent immunoassays. 2021

Hiroyuki Oyama, and Yuki Kiguchi, and Izumi Morita, and Takayuki Miyashita, and Akiyoshi Ichimura, and Hiroko Miyaoka, and Aki Izumi, and Sayaka Terasawa, and Natsumi Osumi, and Hiroki Tanaka, and Toshifumi Niwa, and Norihiro Kobayashi
Kobe Pharmaceutical University, 4-19-1, Motoyama-Kitamachi, Higashinada-ku, Kobe, 658-8558, Japan.

Enzyme-linked immunosorbent assays (ELISAs) are essential for monitoring various biomarkers. Competitive and noncompetitive (sandwich) assay formats are used to determine hapten and macromolecule levels, respectively. Both formats require more sensitive detection of reporter enzymes for greater assay sensitivities. We previously reported the utility of wild-type Gaussia luciferase (wtGLuc) as a fusion partner with antibody single-chain Fv fragments (scFvs) for developing sensitive luminescent ELISAs. Here, we evaluated utility of NanoLuc luciferase (NLuc), a recently developed luciferase, as fusion partner with scFvs from the view of comparison with wtGLuc and a mutant of alkaline phosphatase (ALP'). Thyroxine (T4) and T4-labeled albumin were chosen as model haptenic and macromolecular antigens, respectively. An in-house-prepared anti-T4 scFv was fused with NLuc, wtGLuc, or ALP'. The scFv-NLuc fusion protein showed 47-fold and 29-fold lower limit of detection [LOD; 59 zmol (per assay)] than the wtGLuc- and ALP'-fusions, respectively. In a competitive T4 ELISA, the NLuc-fusion showed 9.3- and 6.3-fold lower LOD, (0.67 pg) than the wtGLuc- and ALP'-fusions, respectively, with a higher specificity in clinical applications. A typical colorimetric ELISA using a peroxidase-labeled second antibody showed 70-fold higher LOD than NLuc-based ELISA. Another advantage of the NLuc-fusion was shown in the sandwich assays; the LOD of T4-labeled albumin (5.0 fmol) was >6-fold lower than that of the other luminescent ELISAs. In an additional sandwich assay developed to count bacteriophage particles, NLuc enabled more sensitive determination than wtGLuc, whereas ALP' showed nearly equivalent performance. Its slowest alteration rate for light intensity after starting the enzyme reaction should enable robust batch-by-batch assay operations. Thus, we concluded that scFv-NLuc fusions serve as suitable probes in various types of immunoassays and may facilitate higher sensitivities with practical specificities.

UI MeSH Term Description Entries
D007118 Immunoassay A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance. Immunochromatographic Assay,Assay, Immunochromatographic,Assays, Immunochromatographic,Immunoassays,Immunochromatographic Assays
D007128 Immunoglobulin Fragments Partial immunoglobulin molecules resulting from selective cleavage by proteolytic enzymes or generated through PROTEIN ENGINEERING techniques. Antibody Fragment,Antibody Fragments,Ig Fragment,Ig Fragments,Immunoglobulin Fragment,Fragment, Antibody,Fragment, Ig,Fragment, Immunoglobulin,Fragments, Antibody,Fragments, Ig,Fragments, Immunoglobulin
D008156 Luciferases Enzymes that oxidize certain LUMINESCENT AGENTS to emit light (PHYSICAL LUMINESCENCE). The luciferases from different organisms have evolved differently so have different structures and substrates. Luciferase
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D006241 Haptens Small antigenic determinants capable of eliciting an immune response only when coupled to a carrier. Haptens bind to antibodies but by themselves cannot elicit an antibody response. Hapten,Contact-Sensitizing Agents,Agents, Contact-Sensitizing,Contact Sensitizing Agents

Related Publications

Hiroyuki Oyama, and Yuki Kiguchi, and Izumi Morita, and Takayuki Miyashita, and Akiyoshi Ichimura, and Hiroko Miyaoka, and Aki Izumi, and Sayaka Terasawa, and Natsumi Osumi, and Hiroki Tanaka, and Toshifumi Niwa, and Norihiro Kobayashi
January 2019, Methods in enzymology,
Hiroyuki Oyama, and Yuki Kiguchi, and Izumi Morita, and Takayuki Miyashita, and Akiyoshi Ichimura, and Hiroko Miyaoka, and Aki Izumi, and Sayaka Terasawa, and Natsumi Osumi, and Hiroki Tanaka, and Toshifumi Niwa, and Norihiro Kobayashi
January 2016, ACS chemical biology,
Hiroyuki Oyama, and Yuki Kiguchi, and Izumi Morita, and Takayuki Miyashita, and Akiyoshi Ichimura, and Hiroko Miyaoka, and Aki Izumi, and Sayaka Terasawa, and Natsumi Osumi, and Hiroki Tanaka, and Toshifumi Niwa, and Norihiro Kobayashi
January 2016, Frontiers in pharmacology,
Hiroyuki Oyama, and Yuki Kiguchi, and Izumi Morita, and Takayuki Miyashita, and Akiyoshi Ichimura, and Hiroko Miyaoka, and Aki Izumi, and Sayaka Terasawa, and Natsumi Osumi, and Hiroki Tanaka, and Toshifumi Niwa, and Norihiro Kobayashi
April 2016, Virus research,
Hiroyuki Oyama, and Yuki Kiguchi, and Izumi Morita, and Takayuki Miyashita, and Akiyoshi Ichimura, and Hiroko Miyaoka, and Aki Izumi, and Sayaka Terasawa, and Natsumi Osumi, and Hiroki Tanaka, and Toshifumi Niwa, and Norihiro Kobayashi
January 2022, FEMS yeast research,
Hiroyuki Oyama, and Yuki Kiguchi, and Izumi Morita, and Takayuki Miyashita, and Akiyoshi Ichimura, and Hiroko Miyaoka, and Aki Izumi, and Sayaka Terasawa, and Natsumi Osumi, and Hiroki Tanaka, and Toshifumi Niwa, and Norihiro Kobayashi
January 2023, Biological & pharmaceutical bulletin,
Hiroyuki Oyama, and Yuki Kiguchi, and Izumi Morita, and Takayuki Miyashita, and Akiyoshi Ichimura, and Hiroko Miyaoka, and Aki Izumi, and Sayaka Terasawa, and Natsumi Osumi, and Hiroki Tanaka, and Toshifumi Niwa, and Norihiro Kobayashi
November 2014, Biochimica et biophysica acta,
Hiroyuki Oyama, and Yuki Kiguchi, and Izumi Morita, and Takayuki Miyashita, and Akiyoshi Ichimura, and Hiroko Miyaoka, and Aki Izumi, and Sayaka Terasawa, and Natsumi Osumi, and Hiroki Tanaka, and Toshifumi Niwa, and Norihiro Kobayashi
April 2023, International journal of molecular sciences,
Hiroyuki Oyama, and Yuki Kiguchi, and Izumi Morita, and Takayuki Miyashita, and Akiyoshi Ichimura, and Hiroko Miyaoka, and Aki Izumi, and Sayaka Terasawa, and Natsumi Osumi, and Hiroki Tanaka, and Toshifumi Niwa, and Norihiro Kobayashi
July 2020, International journal of molecular sciences,
Hiroyuki Oyama, and Yuki Kiguchi, and Izumi Morita, and Takayuki Miyashita, and Akiyoshi Ichimura, and Hiroko Miyaoka, and Aki Izumi, and Sayaka Terasawa, and Natsumi Osumi, and Hiroki Tanaka, and Toshifumi Niwa, and Norihiro Kobayashi
July 2021, Analytical chemistry,
Copied contents to your clipboard!